CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia.

Int J Mol Sci · 2025 · PMC12692354 · PMID 41373778

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among transplant recipients, MRD-negative patients showed a trend toward improved OS (not reached vs. 26 months; p -value of 0.06), although statistical significance was limited by sample size.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.